A recent paper from researchers in China and published in Dove Medical Press investigated whether immune cells called CD8+ T cells and the PD-1/PD-L1 pathway impact overall survival in people with metastatic renal cell carcinoma (mRCC) who are treated with tyrosine kinase inhibitors (TKIs).

The findings from the study suggest that large quantities of CD8+ T cells are significantly associated with longer overall survival in mRCC patients treated with TKIs.

Read the abstract in Dove Medical Press here